Invention Grant
- Patent Title: 3-spiro-7-hydroxamic acid tetralins as HDAC inhibitors
-
Application No.: US15130613Application Date: 2016-04-15
-
Publication No.: US09630922B2Publication Date: 2017-04-25
- Inventor: Pui Yee Ng , Heather Davis , Kenneth W. Bair , David S. Millan , Aleksandra Rudnitskaya , Xiaozhang Zheng , Bingsong Han , Nicholas Barczak , David R. Lancia, Jr.
- Applicant: Forma Therapeutics, Inc.
- Applicant Address: US MA Watertown
- Assignee: Forma Therapeutics, Inc.
- Current Assignee: Forma Therapeutics, Inc.
- Current Assignee Address: US MA Watertown
- Agency: Cooley LLP
- Agent J. Dean Farmer; Serge Banini
- Main IPC: C07D221/20
- IPC: C07D221/20 ; C07D403/04 ; C07D209/96 ; C07D401/04 ; C07D417/06 ; C07D519/00 ; C07D401/06 ; C07D413/06 ; C07D405/04 ; C07D471/04 ; C07D497/10 ; C07D491/107 ; C07D405/06 ; C07D403/06 ; C07D405/10
Abstract:
The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease or neurodevelopmental disease), inflammatory or autoimmune disease, infection, metabolic disease, hematologic disease, or cardiovascular disease.
Public/Granted literature
- US20160304462A1 3-SPIRO-7-HYDROXAMIC ACID TETRALINS AS HDAC INHIBITORS Public/Granted day:2016-10-20
Information query
